Fiscal impact
reports (FIRs) are prepared by the Legislative
Finance Committee (LFC) for standing finance committees of the NM Legislature. The
LFC does not assume responsibility for the accuracy of these reports if they
are used for other purposes.
Current FIRs (in HTML & Adobe PDF formats) are available on the
NM Legislative Website (legis.state.nm.us). Adobe PDF versions include all attachments,
whereas HTML versions may not.
Previously issued FIRs and attachments may
also be obtained from the LFC in
SPONSOR |
|
DATE TYPED |
|
HB |
|
||
SHORT
TITLE |
Hepatitis C Outreach & Treatment Program |
SB |
387 |
||||
|
ANALYST |
|
|||||
APPROPRIATION
Appropriation
Contained |
Estimated
Additional Impact |
Recurring or
Non-Rec |
Fund Affected |
||
FY04 |
FY05 |
FY04 |
FY05 |
||
|
$1,600.0 |
|
|
Recurring |
General
Fund |
|
|
|
|
|
|
Relates to HB 367
LFC Files
Responses
Received From
Department
of Health (DOH)
Health
Policy Commission (HPC)
New
Mexico Public Education Department (NMPED)
SUMMARY
Synopsis of Bill
Senate Bill 387
appropriate $1.6 million from the General Fund for expenditure in FY05 to the
Board of Regents of the University of New Mexico to establish a statewide
hepatitis C virus outreach identification and treatment program, including
patient, community, and professional education.
Significant Issues
According to DOH, the most critical issue facing
the more than 30,000 New Mexicans living with hepatitis C is access to quality
education, medical care, and treatment services. Hepatitis C can be treated in primary care
settings; however, quality care is dependent on excellence in training. Primary care providers learning to manage
hepatitis C disease need regular access to experienced specialists for
consultation.
The University of New
Mexico Health Sciences Center (UNMHSC), in partnership with Department of
Health (NMDOH) and Department of Corrections (NMDOC), has successfully piloted
a telemedicine solution to expand access to hepatitis C treatment. Expansion of this project would improve the
health of New Mexicans living with hepatitis C in rural areas, and could build
a foundation for management of other chronic disease in rural settings.
CHE reports a distinct and major characteristic
of hepatitis C is its tendency to cause chronic liver disease. At least 75
percent of patients with acute hepatitis C ultimately develop chronic infection,
and most of these patients have accompanying chronic liver disease.
FISCAL IMPLICATIONS
The appropriation of
$1,600.0 contained in this bill is a recurring expense to the General Fund. Any
unexpended or unencumbered balance remaining at the end of FY 05 shall revert
to the General Fund.
RELATIONSHIP
SB 387 relates to HB
367, which would make special appropriations for
OTHER SUBSTANTIVE ISSUES
DOH says there are
approximately 42 health care providers in the state providing treatment for hepatitis
C, and many of these providers are clustered in urban areas. Clearly, 42
providers will not be adequate to provide even basic hepatitis C treatment
eligibility evaluation for 30,000 people.
Management of
hepatitis C infection can be complex. Hepatitis C treatment must be closely supervised
by a trained healthcare provider and may require multiple and frequent office
visits, mental health care, and side effect management. Because of these factors, the New Mexico
Hepatitis C Consensus process recommended in 2001 that hepatitis C disease be treated
in primary care settings in communities throughout
Integrating hepatitis
C treatment into primary care settings is most effective when primary care
providers have consistent access to specialists experienced in treating the
disease. This regular access can be
accomplished cost-effectively through telemedicine and Internet technology, and
could also serve to ease feelings of isolation expressed by rural health care
providers. UNMHSC has been successfully
piloting this type of telemedicine learning in partnership with NMDOH and NMDOC
since mid-2003. Patients receiving care
through this learning project have increased access to education and risk
reduction information.
The major high-risk
groups for hepatitis C are:
q
Injection drug users, including those who
used drugs briefly many years ago.
q
People who had blood transfusions before
June 1992, when sensitive tests for anti-HCV were introduced for blood
screening.
q
People who have frequent exposure to
blood products. These include patients with hemophilia, solid-organ
transplants, chronic renal failure, or cancer requiring chemotherapy.
q
Infants born to HCV-infected mothers.
q
Health care workers who suffer
needle-stick accidents.
q
people with high-risk sexual behavior,
multiple partners, and sexually transmitted dis-eases
BD/dm